MOTS-c: Research Overview, Mechanisms, and Current Evidence
MOTS-c (mitochondrial open reading frame of the 12S rRNA type-c) is a 16-amino-acid peptide encoded by the mitochondrial genome. It circulates in the blood as a mitokine and has been studied in preclinical research for roles in metabolism, mitochondrial homeostasis, and exercise-like signaling, which has led to its description as an exercise-mimetic peptide. The information below summarizes published research for educational and research purposes only. It is not medical advice and is not guidance for use in humans.
Available for research use from our preferred vendor, Project Zero. For laboratory research use only.
How It Works (Preclinical Mechanisms)
In preclinical models, MOTS-c has been reported to act on metabolic and mitochondrial pathways, with effects that overlap some of those produced by exercise.
- Reported to activate the AMPK pathway and the folate-AICAR signaling axis linked to energy metabolism.
- Studied for effects on insulin sensitivity and glucose utilization in metabolic models.
- Investigated for promoting mitochondrial biogenesis through markers such as PGC-1-alpha.
- Reported to support plasma membrane repair by facilitating the trafficking of the repair protein TRIM72.
Areas of Research Interest
Published studies have examined MOTS-c in the following research contexts, ranging from cell models to measurements in human blood.
Metabolism and exercise
Studied as an exercise-mimetic mitokine that influences glucose handling and mitochondrial function.
Skeletal muscle protection
Investigated in cachexia and immobilization models for effects on muscle mass and atrophy signaling.
Tissue repair
Examined in membrane-repair and ischemia-reperfusion models for protective effects on cell membranes and heart function.
Aging and disease markers
Studied as a circulating biomarker whose levels change with exercise, ageing, and certain diseases.
Reported Study Parameters
For laboratory research use only. The table below reports the doses and routes used in specific published studies, with sources. It describes what researchers administered in these models and is not a protocol, recommendation, or guidance for use in humans or animals. Animal-study doses are expressed per kilogram of body weight.
| Research Model | Dose and Route Reported | Source |
|---|---|---|
| Differentiated muscle cells (myotubes, in vitro) | 50 uM in culture medium | Jamnick 2026·DOI |
| Cancer cachexia (mouse) | 15 mg/kg, twice daily, intraperitoneal | Jamnick 2026·DOI |
| Human research | Studied mainly as an endogenous mitokine measured in blood; no validated therapeutic dosing regimen established | Elhusseiny 2025·DOI |
Products are supplied as lyophilized powder requiring reconstitution. For reconstitution concentration math, use the Peptide Calculator.
Latest Research (2022 to 2026)
Recent peer-reviewed literature indexed on PubMed continues to characterize MOTS-c in metabolic, muscle, and tissue-repair models, and as a circulating biomarker in humans.
Muscle protection in cachexia (mouse)
A 2026 study reported that MOTS-c at 15 mg/kg twice daily partially protected against skeletal muscle loss in a mouse cancer cachexia model, preserving quadriceps mass and attenuating atrophy signaling, though it did not prevent overall body weight loss. PubMed·DOI
Mitokine response in humans
A 2025 randomized study in active men reported that repeated heat exposure raised circulating MOTS-c levels during calf immobilization, in a pattern comparable to, but not identical to, the response to exercise. PubMed·DOI
Plasma membrane repair (mouse)
A 2024 study reported that MOTS-c supports plasma membrane repair by facilitating trafficking of the protein TRIM72 to the membrane, and that it reduced membrane damage and preserved heart function in an ischemia-reperfusion model. PubMed·DOI
Circulating MOTS-c as a biomarker
A 2022 randomized study measured circulating MOTS-c in breast cancer patients and found no significant change with metformin treatment, illustrating its study as a blood biomarker rather than an administered drug. PubMed·DOI
Research Questions
What is MOTS-c?
MOTS-c is a 16-amino-acid peptide encoded by the mitochondrial genome that circulates as a mitokine and has been studied for roles in metabolism and mitochondrial function, including exercise-like signaling.
What is the current state of human evidence?
Most human research measures naturally circulating MOTS-c in relation to exercise, heat, ageing, or disease. There is no validated regimen for administering MOTS-c as a therapy.
What does the available safety literature suggest?
Because human work centers on measuring endogenous levels rather than dosing, human safety of administered MOTS-c has not been established, and the dosing evidence remains preclinical.
Referenced Citations
Literature indexed on PubMed.
- Jamnick, N.A., et al. (2026). MOTS-c partially protects against skeletal muscle deterioration in C26 cachexia. Front. Med. (Lausanne), 13, 1838178. PubMed·DOI
- Elhusseiny, R., et al. (2025). Repeated heat stress modulates the levels of the mitokines MOTS-c and FGF21 in active men during calf muscle immobilization. Med. Sci. Sports Exerc., 57(12), 2764-2774. PubMed·DOI
- Jia, H., et al. (2024). Mitochondria-encoded peptide MOTS-c participates in plasma membrane repair by facilitating the translocation of TRIM72 to membrane. Theranostics, 14(13), 5001-5021. PubMed·DOI
- Zhang, Z., et al. (2023). MOTS-c: A potential anti-pulmonary fibrosis factor derived by mitochondria. Mitochondrion, 71, 76-82. PubMed·DOI
- Cuyas, E., et al. (2022). Circulating levels of MOTS-c in patients with breast cancer treated with metformin. Aging (Albany NY), 15(4), 892-897. PubMed·DOI
PeptideInfo.org provides information strictly for educational and research purposes. All referenced products are intended for laboratory and research use only and are not approved for human consumption, medical use, or self-administration. Nothing on this page constitutes medical advice. Research summaries reference literature indexed on PubMed.